Invention Grant
- Patent Title: Combined use of FcγRIIb (CD32B) and CD20 specific antibodies
-
Application No.: US16684450Application Date: 2019-11-14
-
Publication No.: US11623005B2Publication Date: 2023-04-11
- Inventor: Mark Cragg , Martin Glennie , Ali Roghanian , Stephen Beers , Peter Johnson , Sean Lim , Bjorn Frendeus , Ingrid Teige
- Applicant: UNIVERSITY OF SOUTHAMPTON
- Applicant Address: GB Southampton
- Assignee: UNIVERSITY OF SOUTHAMPTON
- Current Assignee: UNIVERSITY OF SOUTHAMPTON
- Current Assignee Address: GB Southampton
- Agency: Booth Udall Fuller, PLC
- Agent Rodney J. Fuller
- Priority: GB1013989 20100820
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C12P21/08 ; A61K39/395 ; C07K16/28 ; G01N33/68 ; C07K1/00 ; A61K39/00
Abstract:
The invention provides a method of treating a patient having target cells that express FcγRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcγRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcγRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcγRIIb.
Public/Granted literature
- US20200069798A1 COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD20 SPECIFIC ANTIBODIES Public/Granted day:2020-03-05
Information query
